Physician profile
Neha Patel
NPI 1952531147
$2,888.22
in general payments reported to CMS, 2019-2025
29 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $1,133 · 2023: $481 · 2024: $779 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,611.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $863.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $264.09 | 2021-2025 | |
| Amgen INC. | $204.50 | 2022-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $184.49 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.77 | 2022-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $143.93 | 2022-2024 | Proclaim |
| Bayer Healthcare Pharmaceuticals INC. | $122.24 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $122.14 | 2022-2024 | |
| Medtronic, INC. | $100.48 | 2023-2025 | Intellis Adaptivestim, Vectris Surescan, Inceptiv |
| Astrazeneca Pharmaceuticals LP | $84.04 | 2022-2025 | Farxiga, Airsupra |
| Bausch Health US, LLC | $83.02 | 2022-2023 | Aplenzin, Wellbutrin |
| Ibsa Pharma INC. | $68.08 | 2022 | |
| Pfizer INC. | $55.69 | 2022-2024 | |
| Esperion Therapeutics, INC. | $54.18 | 2024-2025 | Nexletol |
| Astellas Pharma US INC | $47.12 | 2024 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $44.50 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $42.17 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Axsome Therapeutics, INC. | $37.31 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $32.66 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.67 | 2022 | |
| Dexcom, INC. | $19.92 | 2024 | Dexcom G6 Transmitter |
| Eisai INC. | $18.56 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.52 | 2023 | Xifaxan |
| Sumitomo Pharma America, INC. | $16.65 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $14.97 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.81 | 2022 | |
| Amarin Pharma, INC. | $13.80 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.72 | 2022 | |
| Currax Pharmaceuticals LLC | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.